MedTrace Logo

TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma

NCT07053202 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-07-08

No results posted yet for this study

Summary

This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC). The study aims to determine if the combination therapy can more effectively inhibit tumor angiogenesis, improve clinical benefit rates, and prolong survival, while maintaining a high safety profile.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

COMBINATION_PRODUCT

Nivolumab

hepatic artery infusion therapy with nivolumab was performed

PROCEDURE

Transarterial Chemoembolization (TACE)

Seldinger technique for femoral artery puncture. Catheterization to celiac trunk/hepatic artery. Infusion of a mixture of idarubicin, raltitrexed, iodized oil, and contrast agent (approx. 8 mL). Embolization with microspheres (300-500 μm and 500-700 μm).

Sponsors & Collaborators

  • The First Hospital of Hebei Medical University

    lead OTHER

Principal Investigators

  • Wenhua Ma · Department of Oncology, The First Hospital of Hebei Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-11-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053202 on ClinicalTrials.gov